RAMM Pharma Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jackie Peter Burnett
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 200, 82 Richmond Street East Toronto ON Canada M5C 1P1
- IPO Date
- Dec 14, 2020
- Website
- rammpharma.com
- Similar Companies
- Business
- RAMM Pharma Corp. engages in the pharmaceutical and medical product business, focusing on cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals, hemp-based products, and related offerings; it provides pharmaceuticals, cosmetics, and nutraceutaceuticals; resells medical supplies, devices, and consumables; and sells veterinarian products including Cosmetic CBD+CBG formulations. The company operates primarily in Uruguay, Italy, Poland, and Canada, with vertically integrated facilities for cultivation, extraction, processing, production, and distribution through wholly owned subsidiaries such as Canapar Corp., HemPoland Sp. Z o.o., Medic Plast SA, Yurelan SA, and RAMM Pharma Holdings Corp.; HemPoland serves as a licensed producer, contract manufacturer, and distributor of hemp products including CannabiGold-branded items alongside white and private label products. Founded in 1987 and headquartered in Toronto, Canada, at 82 Richmond Street East, the company, formerly known as MTC Growth Fund-I Inc., changed its name in October 2019 to reflect its focus on cannabinoid innovation. In November 2025, RAMM Pharma received minority shareholder approval for a proposed US$5.0 million investment to acquire a 10% equity stake in The Global South S.A.S. at a post-money valuation of US$50 million, including a five-year call option for an additional 15% stake at a future US$400 million valuation, subject to definitive agreements, financing, and regulatory approvals.
RAMM Pharma Corp. Receives Minority Shareholder Approval for Proposed Investment Transaction with The Global South S.A.S.
RAMM Pharma Corp. Provides Additional Disclosure in Connection with its Upcoming Special Meeting of Shareholders
Early Warning Press Release Respecting the Acquisition of Common Shares of RAMM PHARMA Corp.
RAMM Pharma Corp. Provides Update on Canapar
RAMM Pharma Corp. Provides Update on Litigation
RAMM Pharma Corp. Provides Update on Litigation
RAMM Pharma Corp. Announces Corporate Update
RAMM Pharma Corp. Announces Corporate Update
RAMM Pharma Corp. Announces Corporate Update
RAMM Pharma Corp. Announces Corporate Update
RAMM Pharma Corp. Announces Corporate Update.
RAMM Pharma Corp. Announces Corporate Update
RAMM Pharma Corp. Announces Clarification of its Corporate Update of September 12th
RAMM Pharma Corp. Announces Corporate Update
RAMM Pharma Corp. Announces Non-Brokered Private Placement and Intention to Commence Normal Course Issuer Bid
RAMM Pharma Announces Resignation of Director
RAMM Pharma Corp. Announces Intention to Commence Normal Course Issuer Bid
RAMM Pharma Completes Acquisition of Canapar Corp.
Canapar Corp. Receives Shareholder Approval for Business Combination With RAMM Pharma
RAMM Pharma to Acquire 100% of Leading Vertically Integrated European Cannabis Company Canapar Corp.